ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Pfizer Strikes Deal With Malaria Venture

by Michael McCoy
April 27, 2009 | APPEARED IN VOLUME 87, ISSUE 17

Pfizer and Medicines for Malaria Venture have signed an agreement that gives MMV access to Pfizer's library of novel chemical entities. Under the deal, scientists in institutes affiliated with MMV will test about 200,000 Pfizer compounds against Plasmodium falciparum, the parasite that causes malaria. The screening will take place at the Eskitis Institute for Cell & Molecular Therapies at Griffith University, in Australia.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment